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Objective. To determine baseline variables associated with urgency urinary incontinence (UUI) in women presenting for
stress urinary incontinence (SUI) surgery. Methods. Baseline data from two randomized trials enrolling 1,252 women were
analyzed: SISTEr (fascial sling versus Burch colposuspension) and TOMUS (retropubic versus transobturator midurethral sling).
Demographic data, POP-Q measures, and validated measures of symptom severity and quality of life were collected. Charlson
Comorbidity Index (CCI) and Patient Health Questionnaire-9 were measured in TOMUS. Multivariate models were constructed
with UUI and symptom severity as outcomes. Results. Over two-thirds of subjects reported bothersome UUI at baseline. TOMUS
patients with more comorbidities had higher UDI irritative scores (CCI score 0 = 39.4, CCI score 1 = 42.1, and CCI score 2+ =
51.0, 𝑃 = 0.0003), and higher depression scores were associated with more severe UUI. Smoking, parity, prior incontinence
surgery/treatment, prolapse stage, and incontinence episode frequency were not independently associated with UUI. Conclusions.
There were no modifiable risk factors identified for patient-reported UUI in women presenting for SUI surgery. However, the
direct relationships between comorbidity level, depression, and worsening of UUI/urgency symptoms may represent targets for
preoperativeintervention.Furtherresearchisnecessarytoelucidatethepathophysiologicmechanismsthatexplaintheassociations
between these medical conditions and bladder function.
1. Introduction
The presence of stress urinary incontinence (SUI) or urgency
urinary incontinence (UUI) has profound negative impacts
on quality of life, exceeding that of other common morbid
conditions such as diabetes [1]. However, women with both
SUI and UUI—that is, mixed urinary incontinence (MUI)—
h a v eg r e a t e rb o t h e rt h a nt h o s ew i t hS U Ia l o n e[ 2]a n da r e
less likely to have success or cure after undergoing surgical
management of their SUI [3]. While multiple risk factors
for worsening incontinence have been identified including
age, parity, and body mass index [4], there is less known on
whether other demographic variables, concurrent prolapse,
or medical comorbidities may be associated with UUI in
women presenting for surgical treatment of SUI. Better
characterization of these associated variables may identify
targets for intervention to improve outcomes and quality of
life.
Thisstudyisanancillaryanalysisemployingthedatabases
of two large randomized trials of women presenting for
surgicalmanagementofSUI:theTrialofMid-UrethralSlings
(TOMUS) study [5] and the Stress Incontinence Surgical
Treatment Efficacy Trial (SISTEr) [6]. Both studies had large
numbers of patients with MUI. The primary objective of2 Advances in Urology
this study is to determine whether demographic factors,
altered pelvic floor anatomy, or other comorbidities are
associated with UUI among these women presenting for
surgical management of SUI. A secondary goal is to better
characterize the relationships between urgency symptoms
and overall urinary symptom level, anatomic support, and
quality of life measures.
2. Materials and Methods
2.1. Participants. We analyzed baseline data from two IRB-
approved randomized surgical trials for women undergoing
SUI surgery conducted by the Urinary Incontinence Treat-
ment Network (UITN). All participants provided written
informed consent. SISTEr randomized 655 women with
predominant SUI to either an autologous rectus fascial sling
or the Burch colposuspension [6]. The UITN Trial of Mid-
Urethral Slings (TOMUS) study randomized 597 women to
retropubic versus transobturator midurethral slings for SUI
[5]. For both studies, eligibility criteria included a Medical,
Epidemiologic, and Social Aspects of Aging questionnaire
(MESA) stress incontinence symptom score greater than
MESA urge incontinence symptom score and confirmed
observation of leakage by cough and Valsalva stress test
at a standardized bladder volume of 300mL. The SISTEr
trial allowed concomitant abdominal surgery, whereas the
TOMUS trial did not. Both trials allowed concomitant
vaginal surgeries. Women who participated in the SISTEr
trial or who had a prior synthetic sling for SUI or synthetic
mesh which is placed for vaginal reconstructive surgery were
excluded from the TOMUS trial.
2.2. Measures. Baseline demographic data included age, self-
reported race/ethnicity, and education. Body mass index
(BMI, recorded in kg/m
2) was calculated from measured
height and weight. Specific factors which are related to
obstetrical and gynecological history included the number
o fp r e g n a n c i e s( c a t e g o r i z e da s0 ,1 ,2 ,a n d≥3), menopausal
status, hormone replacement therapy, prior hysterectomy,
and prior surgery and/or treatment for urinary incontinence
or pelvic organ prolapse.
2.3. Questionnaires. Subjective urinary incontinence symp-
toms were measured using validated questionnaires: Uro-
genital Distress Inventory (UDI) [7], Incontinence Impact
Questionnaire (IIQ) [7], MESA questionnaire [8], and the
Patient Global Impression of Severity (PGI-S) scale [9].
The UDI measures 3 domains: stress incontinence symp-
toms,irritativesymptoms,andobstructive/discomfortsymp-
toms with bother being measured with a 4-point Likert
scale. The scores from each domain are transformed into a
c o n t i n u o u ss c a l er a n g i n gf r o m0t o1 0 0 ,a n dh i g h e rs c o r e s
indicate greater bother. For the purpose of this analysis,
urgency urinary incontinence was defined as present if a
subject reported urinary leakage related to the feeling of
urgency as “moderate or greatly bothersome” on the UDI.
In addition, the irritative domain was used as a measure of
aw o m a n ’ su r g es y m p t o m s .
The IIQ consists of 30 items that query the impact of
urogenital symptoms on physical functioning, emotional
functioning, travel/mobility, and social functioning using a
4-point Likert scale. Each domain is transformed into a scale
ranging from 0 to 100 with higher values representing more
negative impact.
TheMESAquestionnaireconsistsof15itemstotaldivided
intostressandurgesubscales.AhigherMESAscoreindicates
morefrequen tsym ptomsoverall(rangeof0–45)andforeach
incontinence subscale (range of 0–27 for SUI and range of 0–
18 for UUI).
The following 3 questionnaires were used only in the
T O M U St r i a l .Th eP G I - Sq u e s t i o n n a i r ea s k ss u b j e c t st o
describe“howtheirurinaryconditionisnow”andconsistsof
4 choices for response: normal, mild, moderate, and severe.
The Charlson Comorbidity Index (CCI) encompasses 19
medical conditions weighted from 1 to 6 with total scores
ranging from 0 to 37. A CCI of 3-4 is associated with
52% 1-year mortality [10]. The Patient Health Questionnaire-
9 (PHQ-9) was developed for screening, diagnosing, and
assessing the severity of a depressive disorder. The summary
score ranges from 0 to 27, and a higher score indicates
more depressive symptoms. A validation study of the PHQ-9
showed that a score of 10 appeared to discriminate between
thosewithnodepressivedisorder(<10)andthosewithmajor
depression (≥10) [11].
2.4. Objective Measures. Objective measures included a 24-
hour pad test, POP-Q measurements, and bladder volume at
the time of a positive stress test.
2.5. Statistical Methods. Analyses were carried out in par-
a l l e lf o rt h eS I S T E ra n dT O M U Ss u b j e c t sa st h et r i a l s
had different inclusion and exclusion criteria representing
different populations. Bivariate logistic regression models
werefitconsideringeachcovariateseparatelywithUUIasthe
outcome(UUIisdefinedaspresentifasubjectreportedurine
leakagerelatedtothefeelingofurgencyasmoderately/greatly
bothersome on UDI). Covariates that were statistically and
significantly (𝑃 < 0.05) associated with the odds of UUI in
SISTEr or in TOMUS were considered in the multivariable
model. A final multivariable model was fit to include all the
common covariates from preliminary multivariable models
that were significantly associated with the outcome in either
trial. Urinary incontinence severity (PGI-S), depression, and
thenumberofcomorbiditiesweremeasuredonlyinTOMUS;
these variables were included in the final TOMUS models
as appropriate. Odds ratios (ORs) with corresponding 95%
confidence intervals (CI) were reported.
Linear regression modeling was used to identify asso-
ciations with irritative/urgency symptoms reported on the
UDI and MESA. A similar, yet independent, technique
w a su s e df o rb u i l d i n gt h el i n e a rr e g r e s s i o nm u l t i v a r i a b l e
models. Specifically, covariates that were statistically and
significantly associated with irritative/urgency symptoms
were considered in the multivariable models. For contin-
uous explanatory variables, the slope coefficient for the
association between a particular independent covariate and
UDIirrita tivesubscale/MESAurgesym ptomscon trollingforAdvances in Urology 3
the other covariates in the model was presented. For cat-
egorical covariates, the adjusted mean UDI irritative sub-
scale/MESA urge symptoms controlling for the other covari-
atesinthemodelwasreportedforeachlevelofthecategorical
variable.
All statistical analysis was performed using SAS version
9.2 (SAS Institute, Inc, Cary, NC). A 5% two-sided signifi-
c a n c el e v e lw a su s e df o ra l ls t a t i s t i c a lt e s t i n g .
3. Results
Over two-thirds of women with stress predominant inconti-
nence in both studies reported being moderately or greatly
b o t h e r e db yu r i n el e a k a g er e l a t e dt ot h ef e e l i n go fu r g e n c y
(UUI in 70% in SISTEr and 68% in TOMUS). This is also
reflected in the relatively high mean (standard deviation)
UDI-I (47.8 (25.2) in SISTEr and 41.2 (25.4) in TOMUS)
and MESA urge scores (6.3 (4.0) in SISTEr and 6.2 (4.0)
in TOMUS). The descriptive statistics for the two trials
b a s e do nt h ep r e s e n c eo ra b s e n c eo fU U Ia r es h o w ni n
Table 1. Bivariate analysis revealed that menopausal and
hormone status, education attainment, MESA stress score,
BMI, and IIQ were associated with greater odds of UUI in
both studies (Table 1). It should be noted that a significant
association was not found between UUI and race/ethnicity,
parity ,smoking,orprolapsestage.Aftermultivariateanalysis,
only IIQ score was found to be independently associated
w i t ht h ep r e s e n c eo fU U I .F o re v e r y1 0 - p o i n ti n c r e a s ei n
IIQ score (indicating worse quality of life), there was a 7%
increase in the prevalence of UUI (𝑃 < 0.0001)i nb o t hs t u d y
populations.
Multivariate analyses were carried out using the contin-
uous variables of UDI-I (Table 2)a n dM E S Au r g es c o r e s
(Table 3) to measure bother and severity of LUTS (including
UUI) as an outcome compared to the dichotomous nature
of primary definition of UUI. Race/ethnicity was found to
be significantly associated with UDI-I score in SISTEr but
not in TOMUS (Table 2). For both study populations, the
UDI-I and MESA urge scores were found to differ according
to education achievement, and those subjects with less than
high school education tended to have the highest (or most
bothersome) scores. In TOMUS and SISTEr, pad weight was
independently associated with the severity of UDI-I and
MESA urge; however, the increases in score were small, so
this finding may not be clinically significant. In TOMUS
subjects, higher depression PHQ-9 scores and increasing
number and/or severity of comorbidities (CCI) were asso-
ciated with more severe UUI/urgency symptoms. Age was
also independently associated with greater UUI severity. For
every10-yearincreaseinage,therewasanapproximately0.5-
point increase in MESA urge score. Greater severity (PGI-S)
and bother from stress incontinence on UDI (UDI-S) and
MESA (MESA stress) were associated with worsening UUI
and irritative symptoms.
4. Discussion
Richter et al. demonstrated that higher MESA urge scores
were associated with increased odds of failure after SUI
surgery [3], and in a retrospective review of 464 women,
the presence of UUI was an independent risk factor for
failure after mid-urethral sling [12]. Therefore, we sought
to determine baseline variables associated with UUI and
identifyanymodifiablefactorsthatcouldpotentiallyimprove
SUI surgery outcomes. Although we did find that quality
of life was negatively impacted by the presence of UUI
in both patient populations, we were not able to identify
other patient characteristics that were associated with UUI.
However, when a definition that included a broader range
of irritative LUTS was used, the presence of depression
and more comorbidities were associated with greater bother
and severity of urge-related symptoms in TOMUS subjects,
independent of potential confounders such as age and SUI
severity.
Urgency urinary incontinence commonly coexists in
women undergoing surgery for SUI. More than two-thirds
o ft h e1 2 5 2s u b j e c t sf r o mt h eS I S T E ra n dT O M U Ss t u d i e s
reported“moderatelyorgreatlybothersome”UUIatbaseline.
W ef o u n dn om o d i fi a b l ep a t i e n tc h a r a c t e r i s t i c st h a ta r e
associated with the presence of preoperative bothersome
UUI in this population of women. However, patients with
more comorbidities reported greater bother from LUTS,
a n dh i g h e rd e p r e s s i o ns c o r e sw e r ea s s o c i a t e dw i t hm o r e
severe UUI symptoms. Women with UUI reported worse
incontinence-relatedQoLcomparedtowomenwithoutUUI,
and as bother from irritative LUTS increased, QoL was
negatively impacted. Interestingly, similar to the findings of
Lowder et al. [13], the severity of SUI symptoms predicted
greater UUI symptoms as well as more bother from overall
irritative LUTS. It has also been shown that overall incon-
tinence severity as measured by incontinence episodes or
patient impression of severity is associated with concurrent
urge symptoms in women with SUI [14]. While urgency and
frequency may result from adaptive behaviors to prevent
stress-related leakage, the relationship between SUI and UUI
could represent either greater sphincter dysfunction or more
widespread neuromuscular dysfunction of the pelvic floor.
A g ea n dB M Ih a v eb e e nt h em o s tc o n s i s t e n t l yr e p o r t e d
risk factors associated with UUI in large studies of commu-
nity dwelling women [15, 16]a n dw e r ea l s of o u n dt ob er i s k
factors in a twin study [17]. However, most of those studies
are analyses of population surveys and do not include POP-
Q measurements, voiding diary, or quality of life data. In
the current study, parity, prior UI surgery/treatment, POP-Q
stage, hormonal status, and incontinence episode frequency
were not independently associated with UUI or bother from
UUI and LUTS as measured by the UDI-I and MESA urge.
Our findings that vaginal anatomy and support were not
related to LUTS are consistent with previous studies [18, 19].
Althoughparityhasbeenreportedasariskfactorforurgency
and UUI [17, 20]; when subjects with pure or predominant
UUIarestudied,paritytendstoshowanassociationwithSUI
and/or MUI, but not with UUI [15, 16, 21].
Associations between depression and urinary inconti-
nence have been identified in large population-based cross-
sectional studies [22, 23]a sw e l la sp r o s p e c t i v ec o h o r ts t u d -
ies [21, 24]. Depressive symptoms were more likely to be
reportedbywomenwithincontinencecomparedtocontinent4 Advances in Urology
Table 1: Descriptive statistics by UUI status and results of separate bivariate logistic regression models with outcome of those having UUI.
Results reported separately for the SISTEr and TOMUS trials.
Covariate
SISTEr (𝑁 = 651)T O M U S ( 𝑁 = 593)
Yes
(𝑛 = 455)
No
(𝑛 = 196) 𝑃 value OR
(95% CI)
Yes
(𝑛 = 403)
No
(𝑛 = 190) 𝑃 value OR
(95% CI)
Menopausal status/hormone
replacement therapy 0.002 0.01
No HRT, Postmenopausal 178 (39%) 53 (27%) 1 169 (42%) 74 (39%) 1
Yes HRT, Postmenopausal 156 (34%) 67 (34%) 0.69 (0.46–1.05) 126 (31%) 44 (23%) 1.25 (0.81–1.94)
Premenopausal 120 (26%) 76 (39%) 0.47 (0.31–0.72) 106 (26%) 72 (38%) 0.64 (0.43–0.97)
Prior to UI surgery and/or
treatment 0.01 0.19
No 206 (45%) 110 (56%) 165 (41%) 89 (47%)
Yes 249 (55%) 86 (44%) 1.55 (1.10–2.17) 236 (59%) 101 (53%) 1.26 (0.89–1.78)
Prior to hysterectomy 0.09 0.03
No 306 (67%) 145 (74%) 276 (69%) 147 (77%)
Yes 149 (33%) 51 (26%) 1.38 (0.95–2.01) 125 (31%) 43 (23%) 1.55 (1.04–2.31)
Race/ethnicity 0.16 0.06
Hispanic 56 (12%) 15 (8%) 1.79 (0.98–3.27) 53 (13%) 17 (9%) 1.66 (0.93–2.95)
Non-Hispanic white 323 (71%) 155 (79%) 1 307 (76%) 163 (86%) 1
Non-Hispanic black 34 (7%) 10 (5%) 1.63 (0.79–3.39) 14 (3%) 3 (2%) 2.48 (0.70–8.75)
Non-Hispanic other 41 (9%) 16 (8%) 1.23 (0.67–2.26) 29 (7%) 7 (4%) 2.20 (0.94–5.13)
Parity 0.68 0.48
No pregnancies 16 (5%) 6 (4%) 1 17 (6%) 8 (5%) 1
One pregnancy 25 (7%) 14 (10%) 0.67 (0.21–2.10) 37 (12%) 27 (18%) 0.64 (0.24–1.71)
Two pregnancies 112 (33%) 49 (36%) 0.86 (0.32–2.32) 111 (37%) 51 (34%) 1.02 (0.42–2.53)
Three or more pregnancies 185 (55%) 69 (50%) 1.01 (0.38–2.67) 133 (45%) 65 (43%) 0.96 (0.39–2.35)
Education 0.002 <.0001
48 (11%) 6 (3%) 1 25 (6%) 8 (4%) 1
High school/GED 115 (25%) 56 (29%) 0.26 (0.10–0.64) 109 (27%) 39 (21%) 0.89 (0.37–2.15)
188 (41%) 70 (36%) 0.34 (0.14–0.82) 160 (40%) 57 (30%) 0.90 (0.38–2.11)
BA/BS 56 (12%) 42 (21%) 0.17 (0.07–0.43) 49 (12%) 52 (27%) 0.30 (0.12–0.73)
Grad/Prof 48 (11%) 22 (11%) 0.27 (0.10–0.73) 60 (15%) 34 (18%) 0.56 (0.23–1.39)
Prolapse stage 1 0.34
Stage 0 or 1 110 (24%) 48 (24%) 1 189 (47%) 77 (41%) 1
Stage 2 271 (60%) 116 (59%) 1.02 (0.68–1.53) 183 (45%) 96 (51%) 0.78 (0.54–1.12)
Stage 3+ 74 (16%) 32 (16%) 1.01 (0.59–1.72) 31 (8%) 17 (9%) 0.74 (0.39–1.42)
UI Severity (PGI-S)
∗ N/A 0.001
Normal 38 (9%) 23 (12%) 1
Mild 30 (7%) 30 (16%) 0.61 (0.29–1.25)
Moderate 202 (50%) 97 (51%) 1.26 (0.71–2.23)
Severe 132 (33%) 39 (21%) 2.05 (1.09–3.84)
Depression (PHQ-9)
∗ N/A 0.0001
<10 293 (74%) 165 (88%) 1
10+ (defined as depression) 103 (26%) 22 (12%) 2.64 (1.60–4.34)
Charlson Comorbidity Index
(CCI)
∗ N/A 0.03Advances in Urology 5
Table 1: Continued.
Covariate
SISTEr (𝑁 = 651)T O M U S ( 𝑁 = 593)
Yes
(𝑛 = 455)
No
(𝑛 = 196) 𝑃 value OR
(95% CI)
Yes
(𝑛 = 403)
No
(𝑛 = 190) 𝑃 value OR
(95% CI)
0 287 (71%) 153 (81%) 1
1 69 (17%) 27 (14%) 1.36 (0.84–2.22)
2+ 47 (12%) 10 (5%) 2.51 (1.23–5.10)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
UDI stress score (UDI-S) 79.8 (20.2) 73.8 (25.0) 0.002 1.13 (1.05–1.22) 75.4 (20.6) 72.5 (23.1) 0.13 1.06 (0.98–1.15)
MESA stress score 20.2 (4.1) 17.2 (5.0) <0.0001 1.15 (1.11–1.20) 20.0 (4.2) 17.9 (5.0) <.0001 1.11 (1.06–1.15)
Age (years) 52.2 (10.1) 51.4 (10.8) 0.37 1.08 (0.92–1.27) 53.6 (10.9) 51.3 (10.9) 0.02 1.21 (1.03–1.43)
Body mass index 30.4 (6.3) 28.9 (5.4) 0.003 1.05 (1.02–1.08) 30.7 (7.0) 29.5 (6.2) 0.03 1.03 (1.00–1.06)
IIQ total 190.7 (100.7) 126.3 (87.7) <0.0001 1.07 (1.05–1.09) 169.4
(98.2) 113.4 (83.4) <.0001 1.07 (1.05–1.09)
Pad weight (g) 48.6 (87.6) 31.3 (54.1) 0.01 1.04 (1.01–1.08) 38.1 (66.9) 31.5 (66.6) 0.27 1.02 (0.99–1.05)
∗UI severity, depression, and number of comorbidities were not collected in the SISTEr trial.
Table 2: Final multivariable linear regression models for the SISTEr and TOMUS trials with outcome of UDI-I.
Covariate SISTEr TOMUS
𝑃 value Estimate
∗∗ 𝑃 value Estimate
∗∗
Race/ethnicity 0.001 0.18
Hispanic 41.30 40.46
Non-Hispanic white 48.17 41.24
Non-Hispanic black 55.67 47.06
Non-Hispanic other 52.65 47.80
Education 0.006 <0.0001
<High school 56.23 46.50
High school/GED 50.19 50.52
>High school 49.04 45.27
BA/BS 42.90 38.20
Grad/Prof 48.87 40.20
UI Severity (PGI-S)
∗ <0.0001 .
Normal N/A 42.11
Mild N/A 35.08
Moderate N/A 45.57
Severe N/A 53.80
Charlson Comorbidity Index (CCI)
∗ 0.0003
0N / A 3 9 . 3 5
1N / A 4 2 . 1 1
2+ N/A 50.97
UDI stress score <0.0001 0.17 0.06 0.08
Body mass index 0.002 0.44 0.34 0.13
IIQ total <0.0001 0.11 <0.0001 0.09
Pad weight (10g per unit) 0.03 0.23 0.004 0. 39
∗UI severity and number of comorbidities were not collected in the SISTEr trial.
∗∗For categorical predictors, least squares means are reported, and for continuous covariates, regression coefficients are reported.
women [22], and in a population of subjects greater than 70
years old, depressive mood was a predictor of incident UUI
over a 6-year period [24]. Although it is possible that incon-
tinence as a chronic disease may lead to depression, a recent
study by Melville et al. [25] suggests that major depression
may lead to increased odds of incident incontinence. The
investigators found that subjects with depression were more
likely to develop incontinence over 6 years (OR 1.46, 1.08–
1.97), whereas baseline incontinence did not predict onset of
depression (OR 1.03, 0.75–1.42). Further, there is basic sci-
ence evidence that common biochemical pathways involving
neurotransmitters such as serotonin [26]a n dc o r t i c o t r o p i n6 Advances in Urology
Table 3: Final multivariable linear regression models for the SISTEr and TOMUS trials with outcome urge symptoms from the MESA scale.
Covariate SISTEr TOMUS
𝑃 value Estimate
∗∗ 𝑃 value Estimate
∗∗
Education <0.0001 0.002
<High school 8.21 7.12
High school/GED 6.50 7.15
>High school 6.52 6.65
BA/BS 5.34 5.62
Grad/Prof 6.48 5.90
Depression (PHQ-9)
∗ N/A 0.01
<10 6.06
10+ depression 6.91
MESA stress score <0.0001 0.41 <0.0001 0.41
Age (10 years per unit) 0.001 0.42 <0.0001 0.54
Pad weight (10g per unit) 0.001 0.05 0.0007 0.07
∗Depression information was not collected in the SISTEr trial.
∗∗For categorical covariates, least squares means are reported, and for continuous covariates, regression coefficients are reported.
releasing factor [27] may link the two conditions. Alterations
in these neurotransmitters have been associated with induc-
ing overactive bladder-type symptoms in animal models. In
the few population studies that have differentiated groups
based on type of incontinence, it appears that subjects
with depressive mood may be more likely to report UUI
or MUI compared to SUI [21, 22]. Likewise, although the
difference was relatively small, we also demonstrated that
higher depression scores were associated with more severe
UUI as measured by the MESA urge subscale. Continued
basic science and translational research in this area may
lead to therapeutic targets as well as further clarification
of the central and peripheral neural alterations that lead to
overactive bladder symptoms.
The effect of concomitant medical conditions on UUI
a n dL U T Sw a se v a l u a t e du s i n gt h eC C I ,a n da st h eC C I
score increased, women reported significantly more bother
from LUTS. Similar findings were reported by Nuotio et al.,
who found that older patients with ≥4 chronic diseases had
more than 5 times the risk of developing new UUI (CI 2.03–
15.54)comparedtothosewithfewermedicalconditions[24].
Of note, the CCI does not assess for hypertension which
may impact incontinence symptoms due to antihypertensive
drugs, particularly diuretics [28]. Currently, most of the
published data regarding chronic disease and incontinence
focuses on the metabolic syndrome, and there appears to
be a link between the number of metabolic syndrome
components, including obesity, diabetes, dyslipidemia, and
hypertension and severity of LUTS. In addition, although
the association between diabetes and UUI has been demon-
strated, women with diabetes and metabolic syndrome had
a higher prevalence of LUTS and overactive bladder [29].
However, there was no association between metabolic syn-
drome and International Prostate Symptom Scores in men
and women in another study [30]. It is currently not well
understood whether there is any causality of incontinence
from abnormalities related to metabolic syndrome or other
chronic disease states.
Thestrengthsofthisstudywereitsmulticenterdesignand
inclusion of a large population of well-characterized women
undergoing SUI surgery. The use of validated instruments
andstandardizedanatomiccharacterizationfurtherstrength-
ens our findings. The main limitation of our analysis is the
lack of generalizability to all women with SUI; therefore, our
findings cannot be applied to women with urge predominant
symptoms or who are not undergoing surgery. However,
our study population remains of particular interest given
that greater bothersome baseline urgency symptoms have
been consistently shown to predict patient dissatisfaction in
women undergoing SUI surgery. As over 200,000 women a
year undergo SUI surgery in the United States alone [31],
it is important to identify opportunities to modify these
symptoms in the hopes of improving patient outcomes.
5. Conclusions
Although we did not find any baseline patient variables that
wereassociatedwithUUIinpatientsundergoingSUIsurgery,
interesting questions regarding the effect of systemic medical
conditions on overactive bladder symptoms were raised and
may represent targets for intervention. Why is depression
associatedwithmoresevereUUI?DoesUUIinapatientwith
depression represent a different pathophysiologic condition
than a patient with a more “localized” pelvic floor disorder?
Does the association of number and/or severity of chronic
diseases with worsening of UUI/LUTS indicate a more
systemic problem affecting bladder function that is less likely
to resolve after SUI surgery? Clearly, further investigation
using a well-characterized population and validated pelvic
floorinstrumentsisnecessarytoclarifytheroleofdepression
and concomitant medical conditions in the pathophysiology
of UUI and LUTS in women. In addition, greater emphasis
on “phenotyping” of our patient populations may shed light
on the complex relationship between UUI and SUI and allow
clinicians to more accurately predict surgical outcomes.Advances in Urology 7
Acknowledgments
This work was supported by cooperative agreements from
the National Institute of Diabetes and Digestive and Kidney
Diseases, U01 DK58225, U01 DK58229, U01 DK58234, U01
DK58231, U01 DK60379, U01 DK60380, U01 DK60393, U01
DK60395, U01 DK60397, and 60401. Support was also pro-
vided by the National Institute of Child Health and Human
Development and Office of Research on Women’s Health,
NIH. Dr. Rickey has grant support from Pfizer. Dr. Hsu is
a consultant for AMS. Dr. Mueller is a consultant for and
has grant support from Astellas. For the remaining authors,
nothing was declared.
References
[1] Y. Ko, S.-J. Lin, J. W. Salmon, and M. S. Bron, “The impact of
urinary incontinence on quality of life of the elderly,” American
Journal of Managed Care, vol. 11, pp. S103–S111, 2005.
[2] Y. Dooley, L. Lowenstein, K. Kenton, M. P. FitzGerald, and L.
Brubaker, “Mixed incontinence is more bothersome than pure
incontinence subtypes,” International Urogynecology Journal
andPelvicFloorDysfunction,vol.19 ,no .10,pp .1359–1362,2008.
[3] H. E. Richter, A. Diokno, K. Kenton et al., “Predictors of
treatment failure 24 months after surgery for stress urinary
incontinence,” Journal of Urology,v o l .1 7 9 ,n o .3 ,p p .1 0 2 4 – 1 0 3 0 ,
2008.
[ 4 ]P .S .G o o d e ,K .L .B u r g i o ,H .E .R i c h t e r ,a n dA .D .M a r k l a n d ,
“Incontinenceinolderwomen,”JournaloftheAmericanMedical
Association,v o l .3 0 3 ,n o .2 1 ,p p .2 1 7 2 – 2 1 8 1 ,2 0 1 0 .
[5] H. E. Richter, M. E. Albo, H. M. Zyczynski et al., “Retropubic
versus transobturator midurethral slings for stress inconti-
nence,” The New England Journal of Medicine,v o l .3 6 2 ,n o .2 2 ,
pp. 2066–2076, 2010.
[6] M. E. Albo, H. E. Richter, L. Brubaker et al., “Burch col-
posuspension versus fascial sling to reduce urinary stress
incontinence,” The New England Journal of Medicine,v o l .3 5 6 ,
no. 21, pp. 2143–2155, 2007.
[7] S.A.Shumaker ,J.F .W yman,J.S.Uebersax,D.McClish,andJ.A.
Fanti, “Health-related quality of life measures for women with
urinary incontinence: the incontinence impact questionnaire
and the urogenital distress inventory,” Quality of Life Research,
vol. 3, no. 5, pp. 291–306, 1994.
[8] A. R. Herzog and N. H. Fultz, “Prevalence and incidence
of urinary incontinence in community-dwelling populations,”
JournaloftheAmericanGeriatricsSociety,vol.38,no.3,pp.273–
281, 1990.
[ 9 ] I .Y a l c i na n dR .C .B u m p ,“ V a l i d a t i o no ft w og l o b a li m p r e s s i o n
questionnairesforincontinence,”AmericanJournalofObstetrics
and Gynecology,v o l .1 8 9 ,n o .1 ,p p .9 8 – 1 0 1 ,2 0 0 3 .
[10] M. E. Charlson, P. Pompei, K. A. Ales, and C. R. MacKenzie, “A
new method of classifying prognostic comorbidity in longitu-
dinal studies: development and validation,” Journal of Chronic
Diseases,v o l .4 0 ,n o .5 ,p p .3 7 3 – 3 8 3 ,1 9 8 7 .
[11] K. Kroenke, R. L. Spitzer, and J. B. W. Williams, “The PHQ-
9: validity of a brief depression severity measure,” Journal of
General Internal Medicine,v o l .1 6 ,n o .9 ,p p .6 0 6 – 6 1 3 ,2 0 0 1 .
[12] J .-S.P aick,M.C.Cho ,S.-J .Oh,S.W .Kim,andJ .H.K u,“ F acto rs
influencing the outcome of mid urethral sling procedures for
female urinary incontinence,” Journal of Urology,v o l .1 7 8 ,n o .3 ,
pp. 985–989, 2007.
[ 1 3 ]J .L .L o w d e r ,E .A .F r a n k m a n ,C .G h e t t ie ta l . ,“ L o w e ru r i n a r y
tract symptoms in women with pelvic organ prolapse,” Interna-
tional Urogynecology Journal and Pelvic Floor Dysfunction,v o l .
21, no. 6, pp. 665–672, 2010.
[14] R. C. Bump, P. A. Norton, N. R. Zinner, and I. Yalcin,
“Mixed urinary incontinence symptoms: urodynamic findings,
incontinence severity, and treatment response,” Obstetrics and
Gynecology,v o l .1 0 2 ,n o .1 ,p p .7 6 – 8 3 ,2 0 0 3 .
[ 1 5 ]V .A .M i n a s s i a n ,W .F .S t e w a r t ,a n dG .C .W o o d ,“ U r i n a r y
incontinence in women: variation in prevalence estimates and
risk factors,” Obstetrics and Gynecology, vol. 111, no. 2, pp. 324–
331, 2008.
[ 1 6 ]R .B o t l e r o ,S .R .D a v i s ,D .M .U r q u h a r t ,S .S h o r t r e e d ,a n dR .
J. Bell, “Age-specific prevalence of, and factors associated with,
different types of urinary incontinence in community-dwelling
Australian women assessed with a validated questionnaire,”
Maturitas,v o l .6 2 ,n o .2 ,p p .1 3 4 – 1 3 9 ,2 0 0 9 .
[17] T. L. Gamble, H. Du, P. K. Sand, S. M. Botros, M. Rurak, and R.
P.Goldberg,“Urgeincontinence:estimatingenvironmentaland
obstetrical risk factors using an identical twin study,” Interna-
tional Urogynecology Journal and Pelvic Floor Dysfunction,v o l .
21, no. 8, pp. 939–946, 2010.
[18] C. S. Bradley, M. B. Zimmerman, Q. Wang, and I. E. Nygaard,
“Vaginaldescentandpelvicfloorsymptomsinpostmenopausal
women: a longitudinal study,” Obstetrics and Gynecology,v o l .
111, no. 5, pp. 1148–1153, 2008.
[ 1 9 ]C .G h e t t i ,W .T .G r e g o r y ,S .R .E d w a r d s ,L .N .O t t o ,a n dA .
L. Clark, “Pelvic organ descent and symptoms of pelvic floor
disorders,” American Journal of Obstetrics and Gynecology,v o l .
193, no. 1, pp. 53–57, 2005.
[20] S. Hunskaar, E. P. Arnold, K. Burgio, A. C. Diokno, A. R.
Herzog,andV.T.Mallett,“Epidemiologyandnaturalhistoryof
urinary incontinence,” International Urogynecology Journal and
Pelvic Floor Dysfunction,v o l .1 1 ,n o .5 ,p p .3 0 1 – 3 1 9 ,2 0 0 0 .
[21] L. E. Waetjen, S. Liao, W. O. Johnson et al., “Factors associated
with prevalent and incident urinary incontinence in a cohort of
midlifewomen:alongitudinalanalysisofdata:studyofwomen’s
healthacrossthenation,”AmericanJournalofEpidemiology,vol.
165, no. 3, pp. 309–318, 2007.
[22] J. L. Melville, K. Delaney, K. Newton, and W. Katon, “Incon-
tinence severity and major depression in incontinent women,”
Obstetrics and Gynecology,v o l .1 0 6 ,n o .3 ,p p .5 8 5 – 5 9 2 ,2 0 0 5 .
[23] I.N ygaard,C.T urvey ,T .L.Burns,E.Crischilles,andR.W allace,
“Urinary incontinence and depression in middle-aged United
States women,” Obstetrics and Gynecology,v o l .1 0 1 ,n o .1 ,p p .
149–156, 2003.
[ 2 4 ]M .N u o t i o ,T .L u u k k a a l a ,T .L .J .T a m m e l a ,a n dM .J y l h ¨ a, “Six-
year follow-up and predictors of urgency-associated urinary
incontinence and bowel symptoms among the oldest old: a
population-basedstudy,”ArchivesofGerontologyandGeriatrics,
v o l .4 9 ,n o .2 ,p p .e 8 5 – e 9 0 ,2 0 0 9 .
[ 2 5 ]J .L .M e l v i l l e ,M . - Y .F a n ,H .R a u ,I .E .N y g a a r d ,a n dW .J .
Katon, “Major depression and urinary incontinence in women:
temporal associations in an epidemiologic sample,” American
Journal of Obstetrics and Gynecology,v o l .2 0 1 ,n o .5 ,p p .4 9 0 . e 1 –
490.e7, 2009.
[26] W. D. Steers and K.-S. Lee, “Depression and incontinence,”
World Journal of Urology,v o l .1 9 ,n o .5 ,p p .3 5 1 – 3 5 7 ,2 0 0 1 .
[27] A. P. Klausner and W. D. Steers, “Corticotropin releasing
factor:amediatorofemotionalinfluencesonbladderfunction,”
Journal of Urology, vol. 172, no. 6, pp. 2570–2573, 2004.8 Advances in Urology
[28] E. P. Peron, Y. Zheng, S. Perera et al., “Antihypertensive
drug class use and differential risk of urinary incontinence in
community-dwelling older women,” The Journals of Gerontol-
ogy A,v o l .6 7 ,p p .1 3 7 3 – 1 3 7 8 ,2 0 1 2 .
[29] H.-C. Tai, S.-D. Chung, C.-H. Ho et al., “Metabolic syndrome
components worsen lower urinary tract symptoms in women
with type 2 diabetes,” Journal of Clinical Endocrinology and
Metabolism, vol. 95, no. 3, pp. 1143–1150, 2010.
[ 3 0 ]C .T e m m l ,R .O b e r m a y r ,M .M a r s z a l e k ,M .R a u c h e n w a l d ,S .
Madersbacher, and A. Ponholzer, “Are lower urinary tract
symptomsinfluencedbymetabolicsyndrome?”Urology,vol.73,
no. 3, pp. 544–548, 2009.
[31] J. M. Wu, A. Kawasaki, A. F. Hundley, A. A. Dieter, E. R.
Myers, and V. W. Sung, “Predicting the number of women who
will undergo incontinence and prolapse surgery, 2010 to 2050,”
American Journal of Obstetrics and Gynecology,v o l .2 0 5 ,n o .3 ,
pp. 230.e1–230.e5, 2011.Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com